NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00978549,Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer,https://clinicaltrials.gov/study/NCT00978549,,COMPLETED,"RATIONALE: Analgesics, antiemetics, steroids, and radiation therapy are effective in helping to control symptoms caused by cancer. It is not yet known whether these treatments are more effective when given with or without docetaxel in treating patients with relapsed esophageal cancer or stomach cancer.

PURPOSE: This randomized phase II trial is studying symptom control given together with docetaxel to see how well it works compared with symptom control given without docetaxel in treating patients with relapsed esophageal cancer or stomach cancer.",NO,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer|Gastric Cancer|Nausea and Vomiting|Pain,DRUG: docetaxel|DRUG: steroid therapy|OTHER: questionnaire administration|PROCEDURE: nausea and vomiting therapy|PROCEDURE: pain therapy|PROCEDURE: quality-of-life assessment|PROCEDURE: standard follow-up care|RADIATION: radiation therapy,Overall survival,Time to documented progression (arm I)|Response rate (arm I)|Toxicity (arm I)|Quality of life as assessed by EORTC QLQ-C30 and -STO22|Health economic evaluation as assessed by EQ-5D,,Cambridge University Hospitals NHS Foundation Trust,,ALL,"ADULT, OLDER_ADULT",PHASE3,320,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT,CRCA-COUGAR-02|CDR0000649670|EudraCT-2006-005046-37|ISRCTN13366390|CRUK/07/013|EU-20969,2008-04,2010-04,2010-10,2009-09-17,,2013-08-07,"Bristol Haematology and Oncology Centre, Bristol, England, BS2 8ED, United Kingdom|Addenbrooke's Hospital, Cambridge, England, CB2 2QQ, United Kingdom|Warwick Medical School Clinical Trials Unit, Coventry, England, CV4 7AL, United Kingdom|St. Luke's Cancer Centre at Royal Surrey County Hospital, Guildford, England, GU2 7XX, United Kingdom|Medical Research Council Clinical Trials Unit, London, England, NW1 2DA, United Kingdom|Royal South Hants Hospital, Southampton, England, SO14 0YG, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, AB25 2ZN, United Kingdom|Velindre Cancer Center at Velindre Hospital, Cardiff, Wales, CF14 2TL, United Kingdom",
